Avalo Therapeutics AVTX Business Segments — Research and development expense
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Avalo Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The official record: Avalo Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Avalo Therapeutics's business segments — research and development expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Avalo Therapeutics's business segments — research and development expense?
- Avalo Therapeutics (AVTX) reported business segments — research and development expense of $14.05M in Q1 2026.
- How has Avalo Therapeutics's business segments — research and development expense changed year-over-year?
- Avalo Therapeutics's business segments — research and development expense increased by 54.0% year-over-year, from $9.12M to $14.05M.
- What is the long-term trend for Avalo Therapeutics's business segments — research and development expense?
- Over 2 years (2023 to 2025), Avalo Therapeutics's business segments — research and development expense has grown at a 90.6% compound annual growth rate (CAGR), from $13.78M to $50.09M.
- What does business segments — research and development expense mean?
- The aggregate of all costs incurred to discover, develop, and test new therapeutic candidates within the reportable segment. This is a primary indicator of the company's commitment to innovation and the long-term viability of its product pipeline. Investors use this metric to evaluate the company's investment intensity in future growth opportunities.